People · Operator
Named in public records as an officer, director or promoter · active 2010–2019 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Axon Therapies Inc. | — | Other Technology | Series A | $10.8M | $208.0M | 2016 |
| Coridea NC1, Inc. | — | Biotechnology | Series A | $9.0M | $180.8M | 2010 |
Mark R. Gelfand at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark R. Gelfand on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mitchell S. Bloom | 2 | 7 |
| Paul S. LaViolette | 1 | 3 |
| Neil A. Exter | 1 | 3 |
| Andrew S. ElBardissi | 1 | 2 |
| Steven S. Hochberg | 1 | 2 |
| Howard R. Levin | 1 | 1 |
| Imran S. Eba | 1 | 1 |
| Jonathan S. Wyler | 1 | 1 |
| Neil S. Exter | 1 | 1 |
| Howard R. Levin, M.D. | 1 | 1 |
| Jonathan A. Wyler | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.